Good pick up on the 10k. I agree with your assumption. Libigel success and the revenue the CV and HSDD benefits could generate would allow Biosante to acquire or create a Marketing Division for the company. This would be a big step towards playing with the big boys allowing to keep more of the profits. Remember Biosante still has the Global rights to Elestrin an Bio-t-gel outside the U.S.